Dietary interventions for irritable bowel syndrome

Conditions

Irritable bowel syndrome Digestive System Irritable bowel syndrome

Staudacher HM, Scholz M, Lomer MC, Ralph FS, Irving PM, Lindsay JO, Fava F, Tuohy K, Whelan K.

2020-10-2353 citations

10.1016/j.clnu.2020.10.013

A Diet Low in FODMAPs Reduces Symptoms in Patients With Irritable Bowel Syndrome and A Probiotic Restores Bifidobacterium Species: A Randomized Controlled Trial.

Staudacher HM, Lomer MCE, Farquharson FM, Louis P, Fava F, Franciosi E, Scholz M, Tuohy KM, Lindsay JO, Irving PM, Whelan K.

2017-06-15290 citations

10.1053/j.gastro.2017.06.010

Interventions

Current interventions as of 24/01/2013: 4-week treatment diet + placebo 4-week treatment diet + added probiotic 4-week week sham diet + placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Men and women aged 18-65 years with IBS-D, IBS-M or unsubtyped IBS based on Rome III criteria who do not have a major medical condition (diabetes, psychiatric or current eating disorders) 2. Gastrointestinal disease (e.g. inflammatory bowel disease, coeliac disease) 3. History of previous GI surgery, except cholecystectomy and haemorrhoidectomy

Exclusion criteria

Exclusion criteria: 1. Females who report to be pregnant or lactating 2. Consumption of antibiotics, pre or probiotics (in food products or as supplements) in the last 4 weeks prior to, or during the study 3. Use of unpermitted medications (e.g. biological therapies) 4. Patients who have received bowel preparation for investigative procedures in the 4 weeks prior to the study 5. Patients who have had changes to IBS medications or dose in the 4 weeks prior to the study 6. Abdominal pain or discomfort for less than 2 days in the screening week, the frequency threshold recommended for clinical trials. Exclusion of those with minimal symptoms is recommended, and only those that experience pain on at least two days will be included. 7. Individuals with additional specific dietary needs

Design outcomes

Primary

Measure	Time frame
1. Luminal bifidobacteria concentration between groups at 4 weeks Added 05/08/2014: 2. Proportion of participants with adequate relief of IBS symptoms at 4 weeks	—

Secondary

Measure	Time frame
1. Difference in total and individual luminal gastrointestinal microbiota at 4 weeks 2. Difference in faecal short chain fatty acids and pH between groups at 4 weeks 3. Difference in IBS symptoms between groups at 4 weeks 4. Difference in stool consistency between groups at 4 weeks 5. Difference in nutrient intake between groups at 4 weeks 6. Difference in quality of life (QOL) scores between groups at 4 weeks	—

Measure

Time frame

1. Difference in total and individual luminal gastrointestinal microbiota at 4 weeks 2. Difference in faecal short chain fatty acids and pH between groups at 4 weeks 3. Difference in IBS symptoms between groups at 4 weeks 4. Difference in stool consistency between groups at 4 weeks 5. Difference in nutrient intake between groups at 4 weeks 6. Difference in quality of life (QOL) scores between groups at 4 weeks

—

Countries

United Kingdom

Outcome results

None listed